Literature DB >> 34725477

Pre-engraftment Cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation and its impact on engraftment.

Marcia Garnica1,2, Sylvia Dalcolmo3,4, Bianca Gaio3, Andreia Ribeiro de Almeida4, Juliana Rivello4, Ricardo Bigni4,5, Marcia Rejane Valentim4, Maria Claudia Moreira3,4,5, Angelo Maiolino3,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34725477     DOI： 10.1038/s41409-021-01520-6

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

Review 1.  Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).

Authors:  Per Ljungman; Rafael de la Camara; Christine Robin; Roberto Crocchiolo; Hermann Einsele; Joshua A Hill; Petr Hubacek; David Navarro; Catherine Cordonnier; Katherine N Ward
Journal:  Lancet Infect Dis       Date:  2019-05-29       Impact factor: 25.071

2.  How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Hermann Einsele; Per Ljungman; Michael Boeckh
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

Review 3.  Human cytomegalovirus infection of human hematopoietic progenitor cells.

Authors:  J P Maciejewski; S C St Jeor
Journal:  Leuk Lymphoma       Date:  1999-03

4.  Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment.

Authors:  Carlos Solano; Lourdes Vázquez; Estela Giménez; Rafael de la Cámara; Eliseo Albert; Montserrat Rovira; Ildefonso Espigado; Carmen Martín Calvo; Javier López-Jiménez; María Suárez-Lledó; Anabella Chinea; Albert Esquirol; Ariadna Pérez; Aránzazu Bermúdez; Raquel Saldaña; Inmaculada Heras; Ana Julia González-Huerta; Tamara Torrado; Montserrat Batlle; Santiago Jiménez; Carlos Vallejo; Pere Barba; María Ángeles Cuesta; José Luis Piñana; David Navarro
Journal:  Bone Marrow Transplant       Date:  2020-12-15       Impact factor: 5.483

5.  Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.

Authors:  Per Ljungman; Michael Boeckh; Hans H Hirsch; Filip Josephson; Jens Lundgren; Garrett Nichols; Andreas Pikis; Raymund R Razonable; Veronica Miller; Paul D Griffiths
Journal:  Clin Infect Dis       Date:  2016-09-28       Impact factor: 9.079

6.  Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.

Authors:  Carlos Solano; Estela Giménez; Eliseo Albert; Eva María Mateo; Montserrat Gómez; Rosa Goterris; Ariadna Pérez; Paula Amat; Juan Carlos Hernández-Boluda; Marc Poch; José Luis Piñana; David Navarro
Journal:  Bone Marrow Transplant       Date:  2018-06-13       Impact factor: 5.483

Review 7.  Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Authors:  Lauren Stern; Barbara Withers; Selmir Avdic; David Gottlieb; Allison Abendroth; Emily Blyth; Barry Slobedman
Journal:  Front Microbiol       Date:  2019-05-28       Impact factor: 5.640

8.  Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study.

Authors:  Isabella Martin; Alexandra Valsamakis; Douglas Gladstone; Richard Jones; Richard Ambinder; Robin K Avery
Journal:  Open Forum Infect Dis       Date:  2020-03-09       Impact factor: 3.835

9.  Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.

Authors:  Margaret L Green; Wendy Leisenring; Hu Xie; T Christopher Mast; Yadong Cui; Brenda M Sandmaier; Mohamed L Sorror; Sonia Goyal; Sezen Özkök; Jessica Yi; Farah Sahoo; Louise E Kimball; Keith R Jerome; Morgan A Marks; Michael Boeckh
Journal:  Lancet Haematol       Date:  2016-02-20       Impact factor: 18.959
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.